Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $2.18 Consensus PT from Brokerages

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $2.18.

A number of research analysts have recently commented on ADAP shares. Mizuho dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Scotiabank dropped their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research report on Friday. They set a “buy” rating for the company. Finally, Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics during the third quarter valued at about $95,000. FMR LLC grew its stake in Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Jane Street Group LLC increased its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the period. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in Adaptimmune Therapeutics by 106.5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 94,623 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Price Performance

Adaptimmune Therapeutics stock opened at $0.29 on Friday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $0.54 and its 200 day simple moving average is $0.69. Adaptimmune Therapeutics has a 12 month low of $0.26 and a 12 month high of $1.65. The company has a market cap of $74.41 million, a price-to-earnings ratio of -1.32 and a beta of 2.52.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.